{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T18:56:16Z","timestamp":1780772176195,"version":"3.54.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal des Maladies Vasculaires"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jmv.2014.02.001","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T02:31:34Z","timestamp":1395369094000},"page":"183-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Caract\u00e9ristiques pharmacologiques et cliniques des inhibiteurs directs du facteur Xa\u00a0: rivaroxaban, apixaban, edoxaban et betrixaban"],"prefix":"10.1016","volume":"39","author":[{"given":"S.","family":"Meddahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-M.","family":"Samama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmv.2014.02.001_bib0005","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jama.1967.03130100068022","article-title":"(1890\u20131957), discoverer of heparin","volume":"201","author":"McLean","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.jmv.2014.02.001_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/01.CIR.19.1.97","article-title":"The discovery of dicumarol and in sequels","volume":"19","author":"Link","year":"1959","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.jmv.2014.02.001_bib0015","doi-asserted-by":"crossref","first-page":"e120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"issue":"Suppl. 1","key":"10.1016\/j.jmv.2014.02.001_bib0020","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0398-0499(11)70002-6","article-title":"H\u00e9t\u00e9rog\u00e9n\u00e9it\u00e9 pharmacologique des nouveaux anticoagulants","volume":"36","author":"Samama","year":"2011","journal-title":"J Mal Vasc"},{"issue":"Suppl. 2","key":"10.1016\/j.jmv.2014.02.001_bib0025","first-page":"635","article-title":"Effect of hepatic impairment on the pharmacodynamics and tolerability of rivaroxaban\u00a0\u2013\u00a0an oral, direct factor Xa inhibitor","volume":"5","author":"Halabi","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1177\/0091270006292127","article-title":"Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban\u00a0\u2013\u00a0an oral, direct Factor Xa inhibitor, are not affected by aspirin","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jmv.2014.02.001_bib0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.thromres.2011.12.005","article-title":"Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip of knee arthroplasty","volume":"130","author":"Ericksson","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2014.02.001_bib0040","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2014.02.001_bib0045","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2014.02.001_bib0055","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2014.02.001_bib0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in non-valvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0070","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2014.02.001_bib0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study","volume":"112","author":"B\u00fcller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jmv.2014.02.001_bib0080","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/erc.11.62","article-title":"Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (Einstein-extension study)","volume":"9","author":"Romualdi","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jmv.2014.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0090","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa1111096","article-title":"Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega Jl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1124\/dmd.109.029694","article-title":"In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450\u00a0phenotyping, inhibition and induction studies","volume":"38","author":"Wang","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jmv.2014.02.001_bib0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0110","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jmv.2014.02.001_bib0115","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0120","unstructured":"ClinicalTrials.gov ID: NCT00643201, first received March 20, 2008, last updated on May 17, 2011."},{"key":"10.1016\/j.jmv.2014.02.001_bib0125","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0135","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation (AVERROES Study)","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0140","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jmv.2014.02.001_bib0150","doi-asserted-by":"crossref","first-page":"758385","DOI":"10.1155\/2012\/758385","article-title":"Management of venous thromboembolism in patients with advanced gastrointestinal cancers: what is the role of novel oral anticoagulants?","volume":"2012","author":"Martin","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.jmv.2014.02.001_bib0155","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1110899","article-title":"Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients","volume":"365","author":"Goldhaber","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0160","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0165","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jmv.2014.02.001_bib0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicenter, multinational phase 2\u00a0study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0175","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0180","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bmcl.2009.02.111","article-title":"Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N. N-dimethylcarbamimidoyl) benzamido)-5methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitors","volume":"19","author":"Zhang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jmv.2014.02.001_bib0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1160\/TH08-07-0460","article-title":"A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolism events after total knee replacement (EXPERT)","volume":"101","author":"Turpie","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0190","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2\u00a0randomized dose-ranging study (EXPLORE-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jmv.2014.02.001_bib0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/CCLM.2011.134","article-title":"Laboratory assessment of new anticoagulants","volume":"49","author":"Samama","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0200","first-page":"16","article-title":"Deux nouveaux anticoagulants\u00a0: dabigatran et rivaroxaban. Leur impact sur les examens de laboratoire","volume":"38","author":"Samama","year":"2011","journal-title":"Biotribune"},{"key":"10.1016\/j.jmv.2014.02.001_bib0205","first-page":"8","article-title":"Nouveaux anticoagulants par voie orale\u00a0: quelle place pour les analyses de biologie m\u00e9dicale\u00a0?","volume":"23","author":"Gouin-Thibault","year":"2011","journal-title":"Sang Thrombose Vaisseaux"},{"key":"10.1016\/j.jmv.2014.02.001_bib0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.thromres.2011.09.004","article-title":"Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban","volume":"129","author":"Gerotziafas","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2014.02.001_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.jmv.2014.02.001_bib0220","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.thromres.2012.08.286","article-title":"Do new oral anticoagulants require laboratory monitoring? The clinician point of view","volume":"130","author":"Samama","year":"2012","journal-title":"Throm Res"},{"key":"10.1016\/j.jmv.2014.02.001_bib0225","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u00a0\u2013\u00a0an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2010.04106.x","article-title":"The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study","volume":"9","author":"Tripodi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.thromres.2011.01.001","article-title":"Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement","volume":"127","author":"Freyburger","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jmv.2014.02.001_bib0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11239-012-0803-x","article-title":"Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106\u00a0patients, who have undergone major orthopedic surgery: an observational study","volume":"35","author":"Samama","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jmv.2014.02.001_bib0245","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/1076029611426282","article-title":"Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial","volume":"18","author":"Samama","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0250","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","article-title":"for the rivaroxaban anti-FXa chromogenic assay field trial lab. Evaluation of the anti-Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls","volume":"107","author":"Samama","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0255","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1160\/TH10-03-0204","article-title":"An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma","volume":"104","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0260","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jmv.2012.09.003","article-title":"Questions-r\u00e9ponses sur l\u2019utilisation du rivaroxaban dans le traitement de la maladie thromboembolique veineuse","volume":"37","author":"Pernod","year":"2012","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.jmv.2014.02.001_bib0265","unstructured":"Effective practical management of patients with thromboembolic disorders using rivaroxaban. Symposium at the 58th Annual Meeting of the Scientific and Standardization Committee of the ISTH\u00a0\u2013\u00a0Liverpool (UK) June 28th, 2012."},{"key":"10.1016\/j.jmv.2014.02.001_bib0270","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jmv.2014.02.001_bib0275","doi-asserted-by":"crossref","unstructured":"Van Ryn J, Litzenburger T, Schurer J, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany. Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). AHA 2013 [abstract 9928].","DOI":"10.1161\/circ.126.suppl_21.A9928"},{"key":"10.1016\/j.jmv.2014.02.001_bib0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1160\/TH12-03-0179","article-title":"Reversal of anticoagulant effect of dabigatran and rivaroxaban by non-specific reversal agents: a randomized crossover ex vivo study in healthy volunteers","volume":"108","author":"Marlu","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0285","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1160\/TH12-03-0149","article-title":"Life-threatening bleeding in 4\u00a0patients with an unusual excessive response to dabigatran implications for emergency surgery and resuscitation","volume":"108","author":"Lillo-Le Lou\u00ebt","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0290","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1160\/TH12-03-0184","article-title":"Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery","volume":"108","author":"Rohatagi","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0295","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jth.12230","article-title":"Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-VTE study","volume":"11","author":"Raskob","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmv.2014.02.001_bib0300","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annfar.2011.06.018","article-title":"[Surgery and invasive procedures in patients on long-term treatment with oral direct thrombin or factor Xa inhibitors]","volume":"30","author":"Si\u00e9","year":"2011","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.jmv.2014.02.001_bib0305","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.acvd.2013.04.009","article-title":"Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)\u00a0\u2013\u00a0March 2013","volume":"106","author":"Pernod","year":"2013","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.jmv.2014.02.001_bib0310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jmv.2013.05.005","article-title":"Accidents h\u00e9morragiques des nouveaux anticoagulants","volume":"38","author":"Samama","year":"2013","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.jmv.2014.02.001_bib0315","first-page":"112","article-title":"Dabigatran: a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia","volume":"9","author":"Mirdamadi","year":"2013","journal-title":"ARYA Atheroscler"},{"key":"10.1016\/j.jmv.2014.02.001_bib0320","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMc1303640","article-title":"Nonheparin anticoagulants for heparin-induced thrombocytopenia","volume":"368","author":"Bhatt","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Journal des Maladies Vasculaires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049914000249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0398049914000249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T20:13:30Z","timestamp":1759954410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0398049914000249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0398049914000249"],"URL":"https:\/\/doi.org\/10.1016\/j.jmv.2014.02.001","relation":{},"ISSN":["0398-0499"],"issn-type":[{"value":"0398-0499","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caract\u00e9ristiques pharmacologiques et cliniques des inhibiteurs directs du facteur Xa\u00a0: rivaroxaban, apixaban, edoxaban et betrixaban","name":"articletitle","label":"Article Title"},{"value":"Journal des Maladies Vasculaires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmv.2014.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}